Dupilumab and Tumors: A Review
Author Information
Author(s): Guo Shumeng, Wang Liangchun MD, PhD, Bu Dingfang MD, PhD, Liu Fengjie MD, PhD
Primary Institution: Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China
Hypothesis
What is the safety of dupilumab in patients with pre-existing tumors or those who develop new tumors during treatment?
Conclusion
Dupilumab is generally safe for most patients with cancer, but its effects on Cutaneous T-cell lymphomas (CTCLs) are uncertain.
Supporting Evidence
- Dupilumab has improved the quality of life for patients with atopic dermatitis.
- 90 patients were reviewed, with some developing new tumors after treatment.
- CTCLs were more common among patients who developed new tumors during treatment.
- Most patients showed improvement in atopic dermatitis symptoms.
- Careful monitoring is needed for patients with CTCLs during dupilumab treatment.
Takeaway
Dupilumab helps many people with skin problems, but it might not be good for everyone, especially those with certain types of cancer.
Methodology
A systematic review of 43 articles and analysis of medical records of 90 patients.
Limitations
Small sample size, incomplete clinical data, and short follow-up time.
Participant Demographics
Patients aged 22-82 years, with 50 males and 33 females.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website